Having trouble viewing this email? View in your browser.

This is a promotional email intended for healthcare professionals only.
A link to the Prescribing Information and Adverse Events reporting can be found at the end of this email.
“Expert opinions on the role of antiviral therapy in the management of hospitalised patients with COVID-19: Translating data into practice”

Since the start of the pandemic, Gilead has been focused on supporting you and your patients. Decades of antiviral expertise and commitment have allowed our timely development of VEKLURY (remdesivir), the first and only antiviral treatment approved for COVID-19 patients with pneumonia requiring low- or high-flow oxygen or non-invasive ventilation at the start
of treatment.*2

You can now explore the role of a multifaceted treatment approach in the management of hospitalised patients with COVID-19 in this short, Gilead-sponsored ‘Insights from Clinical Practice’ session, led by Dr David Wohl and Dr Juan Berenguer.
Dr David Wohl   Dr Juan Berenguer
Professor of Medicine, Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, USA Consultant Physician, Infectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Spain
Available on demand on the ECCMID platform, hear our experts discuss a holistic approach to treating hospitalised patients with COVID-19, with a focus on antiviral therapy, and consider how established evidence and emerging data may help to inform future management strategies.
Watch the full session here
In ACTT-1, VEKLURY compared with placebo:
Reduced time to recovery in the overall population (median 10 days vs 15 days, p < 0.001)1
Reduced disease progression to new invasive mechanical ventilation or ECMO in patients who were not receiving either at baseline by 43% (13% vs 23%, absolute difference -10% [95% CI -15 to -4])1
Mortality rate by Day 29 in the overall population was 11% vs 15% (HR: 0.73 [95% CI 0.52–1.03])†1
In a post-hoc subgroup analysis, VEKLURY reduced mortality in patients on low-flow oxygen at baseline by 70% (HR: 0.30 [95% CI 0.14–0.64]
No difference was observed in other baseline oxygen status subgroups
Demonstrated a generally well-tolerated safety profile vs placebo1
Summary of VEKLURY safety profile: The most common adverse event in healthy volunteers was increased transaminases (14%). The most common adverse event in patients with COVID-19 was nausea (4%). Other common adverse events included headache and rash.2 Please refer to the SmPC for a full list of known adverse reactions
DON’T MISS OUT: Other Gilead activities at ECCMID 2021
FLASH SESSION: The role of a multifaceted approach in the management of COVID-19
Leading experts from across the world share their perspectives on the importance of a multifaceted approach and the role of VEKLURY in the management of hospitalised patients with COVID-19 – click here to watch.
INTEGRATED SYMPOSIUM: The role and timing of antiviral therapy in the treatment of COVID-19
This symposium, which examines the science behind antiviral therapy and the rationale for targeting SARS-CoV-2 replication directly, will provide clarity about how, when and why to use antiviral therapy as part of an overall treatment strategy to improve outcomes in patients with COVID-19. Originally broadcast on 10 July, watch the full video in the ‘On demand’ area of the ECCMID platform.
COME VISIT US: Gilead booth
Visit our virtual booth at any time during the congress for more information
on VEKLURY, including video and interactive content. Accessible from the
Gilead company profile page – navigate via the ‘Company Profiles / Booths’
image on the ECCMID homepage or via ‘Company Profiles’ in the menu.
This email includes promotional activities which will include materials and discussion of licensed products and are organised and funded by Gilead Sciences Europe Ltd.
Please click here to access VEKLURY® (remdesivir) Prescribing Information.
* VEKLURY has a conditional marketing authorisation for the treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).2
In some other studies, VEKLURY has not demonstrated a statistically significant difference in mortality benefit.3
ACTT, Adaptive COVID-19 Treatment Trial; CI, confidence interval; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; RDV, remdesivir; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SmPC, summary of product characteristics.
1. Beigel JH, et al. N Engl J Med. 2020; 383: 1813–1826.
2. VEKLURY (RDV) 100 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Available at: medicines.org.uk/emc/product/11597/smpc. Accessed July 2021.
3. WHO Solidarity Trial Consortium. N Engl J Med. 2021; 384: 497–511.
This medicinal product is subject to additional monitoring. This will allow quick identification
of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions via the dedicated COVID-19 Yellow Card reporting site at coronavirus-yellowcard.mhra.gov.uk. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
This information is intended for healthcare professionals only.
July 2021 IHQ-VKY-0033
This email was received because you have opted in to receiving promotional emails from Gilead.
Privacy Policy

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe here.